ArticleFrontiers in pharmacology2023
TED-trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets in Depression With Anhedonia: A Single-Arm, Multicenter Clinical Study.Depression and anxiety · 2025Trial
- Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update.Psychopharmacology bulletin · 2026Review
- A narrative review on trazodone as a multimodal and multifunctional antidepressant: clinical relevance of formulations, dosing, and pharmacokinetic/pharmacodynamic targets.Annals of general psychiatry · 2026Review
- Expert consensus on the use of trazodone in patients with major depressive disorder: results from a European Delphi panel.European psychiatry : the journal of the Association of European Psychiatrists · 2026Article
- The value of observational studies in MDD research based on the example of trazodone once-a-day.Neuroscience applied · 2026Article
- Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors.Frontiers in psychiatry · 2026Article
- Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management.International journal of molecular sciences · 2026Review
- Trazodone effectiveness in depression (TED): a comparative evaluation of effect sizes trazodone extended release and SSRIs in the treatment of major depressive disorder.Frontiers in pharmacology · 2026Article
- Managing depression in the elderly: real-world clinical considerations and perspectives.International clinical psychopharmacology · 2025Article
- PtNiSnOInternational journal of molecular sciences · 2025Article
- Anhedonia: Current and future treatments.PCN reports : psychiatry and clinical neurosciences · 2025Review
- Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment.Frontiers in psychiatry · 2025Article
- Insulin Resistance, Temperament and Personality Traits Are Associated with Anhedonia in a Transdiagnostic Sample.Brain sciences · 2024Article
- Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.